Abstract

The purpose of the contract is to 1) establish qualified clinical research units that, by building of existing research resources at the host Institution and combining the necessary expertise in clinical pharmacology and child psychiatry, can become national resources where studies ont he safety and efficacy of psychotropic medications can be conducted in a prompt and cost effective manner; and 2) fund selected research projects of particular public health significance, in particular in the area of autism and other pervasive developmental disorders, to be conducted at these units. The units, together with the already funded RUPPs will work as a network of research sites and conduct high priority clinical studies in various pediatric ages, conducting research on various aspects of pediatric psychopharmacology, including (but not limited to): dose ranges, dosing regimen, pharmacokinetics, general safety profile, efficacy and effectiveness, and effects on cognition, behavior and development. To establish research units of where clinical studies on the safety, efficacy, pharmacokinetics and pharmacodynamics of psychotropic medications can be investigated in children and adolescents, in general, and in patients suffering from autism and other pervasive developmental disorders in particular. To conduct a minimum of 2 studies at each research unit (of which one shall be a clinical efficacy trial and the other a pharmacokinetic and/or pharmacodynamic dose finding study or a pilot efficacy and tolerability study) during the 3 years of the contract. In addition, if the two year option is exercised, at least another two similar studies (i.e., one efficacy trial and one pharmacokinetic and/or pharmacodynamic dose finding study) shall be conducted. To spur the conduct of other clinical trials and studies in pediatric psychopharmacology to be funded through mechanisms other than this contract (i.e., investigator-initiated grants from federal agencies, private foundations, and pharmaceutical companies).

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research and Development Contracts (N01)
Project #
N01MH070009-007
Application #
6323833
Study Section
Project Start
1997-09-30
Project End
2000-09-30
Budget Start
2000-06-07
Budget End
2001-03-31
Support Year
Fiscal Year
2000
Total Cost
Indirect Cost

  Institution

Name
Yale University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520

  Publications

Scahill, Lawrence; Sukhodolsky, Denis G; Anderberg, Emily et al. (2016) Sensitivity of the modified Children's Yale-Brown Obsessive Compulsive Scale to detect change: Results from two multi-site trials. Autism 20:145-52
Levine, S Z; Kodesh, A; Goldberg, Y et al. (2016) Initial severity and efficacy of risperidone in autism: Results from the RUPP trial. Eur Psychiatry 32:16-20
Aman, Michael; Rettiganti, Mallikarjuna; Nagaraja, Haikady N et al. (2015) Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial. J Child Adolesc Psychopharmacol 25:482-93
Hallett, Victoria; Lecavalier, Luc; Sukhodolsky, Denis G et al. (2013) Exploring the manifestations of anxiety in children with autism spectrum disorders. J Autism Dev Disord 43:2341-52
Nurmi, E L; Spilman, S L; Whelan, F et al. (2013) Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. Transl Psychiatry 3:e274
Scahill, Lawrence; Hallett, Victoria; Aman, Michael G et al. (2013) Brief Report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. J Autism Dev Disord 43:739-46
Tobiasova, Zuzana; van der Lingen, Klaas H B; Scahill, Lawrence et al. (2011) Risperidone-related improvement of irritability in children with autism is not associated with changes in serum of epidermal growth factor and interleukin-13. J Child Adolesc Psychopharmacol 21:555-64
Arnold, L Eugene; Farmer, Cristan; Kraemer, Helena Chmura et al. (2010) Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. J Child Adolesc Psychopharmacol 20:83-93
Hoekstra, Pieter J; Troost, Pieter W; Lahuis, Bertine E et al. (2010) Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene. J Child Adolesc Psychopharmacol 20:473-7
Jahromi, Laudan B; Kasari, Connie L; McCracken, James T et al. (2009) Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord 39:395-404

Showing the most recent 10 out of 19 publications